Comparison of Mayo And HFA-ICOS Cardiotoxicity Risk Score Validity for Predicting Cardiotoxicity in Anthracycline Chemotherapy Patients

Abstract

Background: Anthracycline can cause cardiotoxicity. In estimating the risk of cardiotoxicity, various risk prediction scores have been developed. Mayo cardiotoxicity risk score has long been used. The newest protocol is the HFA-ICOS cardiotoxicity risk score. There have been no studies that directly compare the validity of these scores. Objective: This study aims to compare the validity of the Mayo and HFA-ICOS cardiotoxicity risk scores for predicting cardiotoxicity in anthracycline chemotherapy patients. Method: This research was a retrospective cohort. It began by searching for patients who underwent baseline evaluation before anthracycline chemotherapy in a tertiary hospital. Seventy patients who met the criteria were included. Baseline data was used for cardiotoxicity risk score assessment. Cardiotoxicity follow-up was carried out with echocardiography. Statistical analysis was carried out using STATA Se 17.0 statistical software. Result: Twenty of 70 patients (28.6%) experienced cardiotoxicity. The average total dose of doxorubicin used was 433.8 mg/m2. The majority of patients were women. The most common cardiovascular risk factor was hypertension. The AUC for the Mayo cardiotoxicity risk score was 0.695 (sensitivity 65%, specificity 74 %). The HFA-ICOS cardiotoxicity risk score was 0.59 (sensitivity 30 %, specificity 88 %). The Mayo cardiotoxicity risk score is better to role-out cardiotoxicity (NPV 84.1%) compared to the HFA-ICOS cardiotoxicity risk score (NPV 75.9%). Conclusion: There is a difference between Mayo and HFA-ICOS validity for predicting cardiotoxicity. Overall, the Mayo cardiotoxicity risk score is better compared to the HFA-ICOS cardiotoxicity risk score.